Cumberland Pharmaceuticals (CPIX) and SciClone Pharmaceuticals said Tuesday that China's National Medical Products Administration has approved Vibativ injection, a treatment for patients with hospital-acquired and ventilator-associated pneumonia.

The companies said the approval follows an agreement granting SciClone exclusive rights to register, promote, and distribute Vibativ in the country.

The two companies plan to launch the product in China later this year, they added.